Zogenix, Inc. (ZGNX)
(Delayed Data from NSDQ)
$38.02 USD
-0.18 (-0.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $38.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.02 USD
-0.18 (-0.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $38.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zogenix (ZGNX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zogenix (ZGNX) delivered earnings and revenue surprises of 9.52% and -42.73%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study
by Zacks Equity Research
Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.
Options Traders Expect Huge Moves in Zogenix (ZGNX) Stock
by Zacks Equity Research
Investors need to pay close attention to Zogenix (ZGNX) stock based on the movements in the options market lately.
Zogenix Gets Refusal to File Letter From FDA for Seizure Drug
by Zacks Equity Research
Zogenix (ZGNX) receives a Refusal to File letter from the FDA regarding its NDA for Fintepla for the treatment of seizures associated with Dravet syndrome.
Zogenix Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Zogenix has been struggling lately, but the selling pressure may be coming to an end soon.
Zogenix (ZGNX) in Focus: Stock Moves 9.8% Higher
by Zacks Equity Research
Zogenix (ZGNX) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
Zogenix's Epilepsy Candidate Successful in Phase III Study
by Zacks Equity Research
Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.
Are Options Traders Betting on a Big Move in Zogenix (ZGNX) Stock?
by Zacks Equity Research
Investors in Zogenix (ZGNX) need to pay close attention to the stock based on moves in the options market lately.
Why Earnings Season Could Be Great for Zogenix (ZGNX)
by Zacks Equity Research
Zogenix (ZGNX) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Implied Volatility Surging for Zogenix (ZGNX) Stock Options
by Zacks Equity Research
Zogenix (ZGNX) needs investors to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Zogenix (ZGNX) Stock Options
by Zacks Equity Research
Zogenix (ZGNX) needs Investors to pay close attention to the stock based on moves in the options market lately.
Company News For Oct 2, 2017
by Zacks Equity Research
Companie in the news are: KBH,TSN,IVZ,ZGNX
Zogenix (ZGNX) Stock Skyrocketed Over 170% Today: Here's Why
by Madeleine Johnson
On Friday, shares of pharmaceutical company Zogenix Inc. (ZGNX) are skyrocketing after it announced positive results from its first Phase 3 study of ZX008, a drug used to treat the rare epilepsy form Dravet Syndrome.
Are Options Traders Betting on a Big Move in Zogenix (ZGNX) Stock?
by Zacks Equity Research
Investors in Zogenix (ZGNX) need to pay close attention to the stock based on moves in the options market lately.
Zogenix, Inc. (ZGNX) Jumps: Stock Rises 5.2%
by Zacks Equity Research
Zogenix, Inc. (ZGNX) was a big mover last session, as the company saw its shares rise over 5% on the day.
Are Options Traders Betting on a Big Move in Zogenix (ZGNX) Stock?
by Zacks Equity Research
Zogenix (ZGNX) warrants investors' attention based on moves in the options market lately.